We expect that this new outcome measure, together with bioelectric measurments of CFTR function in sweat glands and nasal epithelia [13], [53], will help to determine the level of functional correction that is required in different organ systems to achieve therapeutic benefits in CF patients. The gene discussed is CFTR; the disease is cystic fibrosis.